- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: Cyanein, Decumbin 中文名稱:布雷菲德菌素A
Brefeldin A (BFA)作用于HCT 116細胞,抑制內(nèi)酯抗生素和ATPase,作用于protein transport(蛋白轉(zhuǎn)運),IC50為0.2 μM,誘導(dǎo)癌細胞分化和凋亡。它還能提高同源重組修復(fù)效率,是CRISPR-mediated HDR的增強劑。Brefeldin A 也是自噬和線粒體自噬的抑制劑。
Brefeldin A (BFA) Chemical Structure
CAS: 20350-15-6
規(guī)格 | 價格 | 庫存 | 購買數(shù)量 |
---|---|---|---|
10mM (1mL in DMSO) | 655.27 | 現(xiàn)貨 | |
5mg | 571.63 | 現(xiàn)貨 | |
25mg | 2235.02 | 現(xiàn)貨 | |
100mg | 5490.64 | 現(xiàn)貨 | |
1g | 28665 | 現(xiàn)貨 | |
更大包裝 有超大折扣 | |||
400-668-6834 |
|||
相關(guān)靶點 | V-ATPase F-ATPase SERCA RecA AAA ATPase family | 點擊展開 |
---|---|---|
相關(guān)產(chǎn)品 | (-)-Blebbistatin CB-5083 Omecamtiv mecarbil (CK-1827452) Thapsigargin Sodium orthovanadate Ouabain Golgicide A BTB06584 Ginsenoside Rb1 CDN1163 Periplocin Rhodamine 123 tetrathiomolybdate Saikosaponin D | 點擊展開 |
相關(guān)化合物庫 | FDA藥物庫 天然產(chǎn)物庫 離子通道配體庫 外泌體分泌相關(guān)化合物庫 鈣通道阻滯劑庫 | 點擊展開 |
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
HeLa? | Function Assay | 5 μg/ml | 3 h | causes nuclear exclusion of the FoxO1 transcription factor and decreases transcription of FoxO1-regulated genes | 24843827 |
3T3-L1 | Function Assay | 5 μg/ml | 1?h | causes phosphorylation of the FoxO1 transcription factor | 24843827 |
3T3-L1 | Function Assay | 5 μg/ml | 1?h | causes redistribution of GLUT4 but not increase in glucose uptake | 24843827 |
3T3-L1 | Function Assay | 5 μg/ml | 30 min | causes reversible redistribution of GLUT4 | 24843827 |
3T3-L1 | Function Assay | 5 μg/ml | 30 min | recapitulates insulin action with respect to regulating Akt activity and AS160 phosphorylation | 24843827 |
3T3-L1 | Function Assay | 5 μg/ml | 30 min | mimics the effects of insulin and causes robust phosphorylation of Akt (Ser 473) and phosphorylation of AS160 (Thr 642 and Ser 588) | 24843827 |
H838-KDLKB1? | Function Assay | 30?ng/ml | 12/18 h | increases the levels of phosphorylated eIF2α (phospho-eIF2α) | 25011082 |
H838-KDLKB1? | Function Assay | 30?ng/ml | 12/18 h | increases the protein levels of BiP? | 25011082 |
H838-LKB1 | Function Assay | 30?ng/ml | 12/18 h | increases the protein levels of BiP? | 25011082 |
HepG2? | Function Assay | 1μg/mL | 3–24?h | increases the level of APE1 in a time-dependent manner | 25026174 |
Huh-7? | Function Assay | 1μg/mL | 3–24?h | increases the level of APE1 in a time-dependent manner | 25026174 |
RBE4 | Function Assay | 2?μM | 3–24?h | induces an overload of Ca2+?in the mitochondria in the first 6?h of incubation (p?<?0.001) but Ca2+?levels in this organelle decreased after 12?h of incubation | 25128025 |
RBE4 | Function Assay | 2?μM | 3–24?h | induces a delayed depletion of the ER Ca2+?content at 6?h of incubation significantly | 25128025 |
RBE4 | Function Assay | 2?μM | 3–24?h | increases the levels of ROS time-dependently | 25128025 |
RBE4 | Function Assay | 2?μM | 3–24?h | increases active caspase-12 in a time-dependent manner? | 25128025 |
RBE4 | Function Assay | 2?μM | 3–24?h | increases the XBP1 protein levels after 3 and 6?h of treatment | 25128025 |
RBE4 | Apoptosis Assay | 2?μM | 3–24?h | induces apoptosis time dependently | 25128025 |
HEK293/hERG | Function Assay | 10?μM | 1?h | results in a time-dependent reduction mature hERG protein? | 25218469 |
MEC | Function Assay | 1 μM | 1.5 h | causes a dramatic decrease in the surface VEGFR2 | 25228815 |
KMS-6 | Function Assay | 1?μM? | 24 h | exhibits half the secretion of galanin-LI as did the control | 25229126 |
A172 | Function Assay | 10?μg/ml | 4?h | results in the retrograde transport of fluorescent granules | 25239507 |
MDA-MB-231 | Function Assay | 0–50 μg/mL | 24 h | inhibits the formation of 3D and 2D colonies | 25356567 |
MDA-MB-231 | Apoptosis Assay | 0.05–1 μg/mL | 24 h | induces PARP (poly ADP-ribose polymerase-1) cleavage | 25356567 |
MDA-MB-231 | Growth Inhibition Assay | 0.01/0.05 μg/mL | 24 h | increases the fraction of sub-G1 cell debris | 25356567 |
MDA-MB-231 | Apoptosis Assay | 0.1 μg/mL | 4 h | induces apoptosis | 25356567 |
MDA-MB-231 | Cell Viability Assay | 0–50 μg/mL | 48 h | EC50?= 0.016 μg/mL | 25356567 |
H1299 | Function Assay | 10 μg/ml | 24 h | induces autophagy? | 25388970 |
PEXEL-Nluc | Function Assay | 5 mg/mL | 6 h | causes an increase in reporter activity in the parasite | 25392998 |
SP-Nluc | Function Assay | 5 mg/mL | 6 h | causes an increase in reporter activity in the parasite | 25392998 |
iPSC-CMs? | Function Assay | 500 ng/ml | 48 h | increases the intensity of the higher mobility LAMPs at the cost of the lower mobility species | 25488666 |
OB-6 | Apoptosis Assay | 2.7?μM | 48 h | induces apoptosis | 25532480 |
SMCs | Function Assay | 1μg/mL | 3 h | accumulates CNPY2 protein in the ER compartment and no longer co-localized with the Golgi marker? | 25589425 |
HepG2? | Function Assay | 1?μM? | 24 h | decreases the level of PXR mRNA | 25616597 |
FRT? | Function Assay | 5 μg/ml | 2?h | prevents the increase in cleaved α subunits when [Na+]i?was reduced | 25767115 |
FRT? | Function Assay | 5 μg/ml | 2?h | blocks trafficking through the Golgi complex by inhibiting ER-to-Golgi transport | 25767115 |
nHDFs? | Function Assay | 1?μM? | 2?h | prevents the assembly of cytosolic coat proteins onto Golgi membranes | 25772616 |
DF1? | Function Assay | 1?μM? | 48 h | disperses?the exogenous CSGalNAcT2 protein | 25807054 |
COS | Function Assay | 1 μg/ml | 3 h | completely disperses the AP-1 signal? | 25915900 |
HeLa | Function Assay | 200?ng/ml | 3 h | induces the artificial break-up of the Golgi complex | 25948586 |
NRK | Function Assay | 200?ng/ml | 4?h | rescues mitotic progression | 25948586 |
Caco-2 | Function Assay | 2.5 μM | 30 min | attenuates the TGF-β1-mediated increase in SERT function | 25954931 |
HUVEC | Function Assay | 10?μM | 1?h | increases?the number and intensity of fluorescent areas especially in perinuclear space | 25956988 |
HUVEC | Function Assay | 10?μM | 1?h | abolishes hypoxia-induced release of ATP from apical and basolateral surfaces | 25956988 |
HEMC-1 | Function Assay | 0.1?μg/ml | 24?h | causes a higher inhibitory effect on exocytosis than nocodazole | 25972759 |
SMCs | Function Assay | 10?μg/ml | 0-12 h | causes a transient Ca2+?release from the ER/SR? | 26172080 |
SMCs | Function Assay | 10?μg/ml | 0-12 h | shows a trend towards a higher concentration of the ER/SR network in the perinuclear area? | 26172080 |
MEFs VAMP7 KO | Function Assay | 5?μM | 20 min | causes resident enzymes such as NAGT-GFP, to diffuse back to the ER | 26196023 |
MEFs WT | Function Assay | 5?μM | 20 min | causes resident enzymes such as NAGT-GFP, to diffuse back to the ER | 26196023 |
C2C12 | Function Assay | 1?μg/ml | 1?h | abolishes cytokine release from C2C12 myotubes | 26291279 |
PC12 | Function Assay | 2 μM | 1 h | inhibits the L-DOPA (20?μM)-induced transient ERK1/2 phosphorylation? | 26363191 |
HEK293 | Function Assay | 5?μg/ml | 12?h | abolishes CMA-induced CRELD2 secretion | 24687431 |
COS-1 | Function Assay | 5 μg/ml | 24 h? | restricts localization of NB in the perinuclear region? | 24671751 |
RAW264.7 | Apoptosis Assay | 4 μM | 48 h | attenuates the inhibition of ox-LDL-induced apoptosis and the facilitation of cholesterol efflux by Ac-hE-18A-NH2 | 24639032 |
MDMs | Apoptosis Assay | 10?μg/ml | 12/15 h | induces apoptosis | 24556695 |
PMHs? | Function Assay | 10–20?μg/ml | 24?h | induced ER stress | 24407242 |
PMHs? | Apoptosis Assay | 10–20?μg/ml | 24?h | increases cell death | 24407242 |
HEK293/tau | Function Assay | 5 μM | 1/2/4 h | induces Golgi fragmentation? | 24368089 |
HEK293/tau | Function Assay | 5 μM | 3 h | induces tau hyperphosphorylation | 24368089 |
ADF | Function Assay | 10 μM | 16 h | inhibits the ZnCl2-induced translocation of CRT | 24228232 |
U373? | Function Assay | 10 μM | 16 h | inhibits the ZnCl2-induced translocation of CRT | 24228232 |
RKO-HIPK2i | Function Assay | 10 μM | 16 h | inhibits the ZnCl2-induced translocation of CRT | 24228232 |
ADF? | Function Assay | 10 μM? | 6 h | impairs the DC activation | 24228232 |
Huh7 | Function Assay | 5 μg/ml | 4 h | abolishes the secretion of intracellular ApoB | 24100140 |
Huh7 | Function Assay | 5 μg/ml | 1 h | causes a significant increase in ApoB-crescents | 24100140 |
Huh7 | Function Assay | 5–10?ng/ml | 12 h | increases ApoB-crescents without inhibiting secretion | 24100140 |
BAECs | Function Assay | 5 μg/ml | 0-4 h | induces the rapid dephosphorylation of eNOS at Ser1179 | 24085225 |
Macrophages | Function Assay | 71 μM | 6 h | inhibits lunasin internalization? | 24039740 |
Colo 205 | Growth Inhibition Assay | 0-5 μg/mL | 48 h | inhibits cell growth in suspension cultures with an estimated IC50 of ~15 ng/mL | 23973996 |
Colo 205 | Function Assay | 0.012-0.025 μg/mL | 14 d | reduces the clonogenicity of Colo 205 CSCs | 23973996 |
Colo 205 | Apoptosis Assay | 0.1 μg/mL | 0-24 h | induces apoptosis of Colo 205 cells in suspension cultures | 23973996 |
Colo 205 | Function Assay | 0.015 μg/mL | 24 h | induces the expression of ER stress-related genes | 23973996 |
Colo 205 | Function Assay | 0.015 μg/mL | 24 h | inhibits the activity of MMPs | 23973996 |
IBRS2 | Function Assay | 5 μg/ml | 0.5 h | disrupts the ERGIC and Golgi? | 23963534 |
IBRS2 | Function Assay | 5 μg/ml | 0.5 h | enhances FMDV infection | 23963534 |
HeLa | Function Assay | 2 μM | 2 h? | attenuates the TNF-induced secretion of IL-15 | 23950892 |
HFS? | Function Assay | 0-1 μg/ml | 24 h | GLTP expression reaches a plateau at concentrations as low as 0.01 μg/ml | 23894633 |
HFS? | Function Assay | 0.01 μg/ml | 24 h | increases the expression of glycosphingolipid synthase genes at 6 h | 23894633 |
OVCAR-3 | Growth Inhibition Assay | 1–15?μM? | 24?h | induces a loss of cell viability dose dependently? | 23826964 |
OVCAR-3 | Function Assay | 1–15?μM? | 24?h | induces nuclear damage | 23826964 |
OVCAR-3 | Apoptosis Assay | 1-10?μM | 4 h | induces the activation of apoptosis-related proteins | 23826964 |
OVCAR-3 | Apoptosis Assay | 10?μM | 24?h | induces activation of caspases | 23826964 |
OVCAR-3 | Function Assay | 1–10?μM | 24?h | induces disruption of the mitochondrial transmembrane potential | 23826964 |
OVCAR-3 | Function Assay | 1–10?μM | 24?h | induces formation of reactive oxygen species | 23826964 |
OVCAR-3 | Function Assay | 1–10?μM | 24?h | inhibits cell adhesion and migration | 23826964 |
HeLa | Function assay | 100 uM | 2 hrs | Dispersion of cis golgi marker betaCoP in human HeLa cells at 100 uM for 2 hrs | 17563369 |
HeLa | Function assay | 100 uM | 2 hrs | Dispersion of cis golgi marker KDEL in human HeLa cells at 100 uM for 2 hrs | 17563369 |
Vero | Function assay | 10 ug/ml | 5 mins | Inhibition of Arf1 in african green monkey Vero cells assessed as rapid AP-1 dispersal from golgi membranes at 10 ug/ml after 5 mins by immunofluorescence method | 19182783 |
Vero | Function assay | 10 ug/ml | 5 mins | Inhibition of Arf1 in african green monkey Vero cells assessed as rapid GGA3 dispersal from trans golgi network at 10 ug/ml after 5 mins by immunofluorescence method | 19182783 |
Vero | Function assay | 10 uM | 1 hr | Inhibition of GBF1 QNV deleted mutant in african green monkey Vero cells assessed as effect on change in golgi morphology at 10 uM after 1 hr by immunofluorescence method | 19182783 |
Vero | Function assay | 10 uM | 1 hr | Inhibition of GBF1 QNV to AAA mutant in african green monkey Vero cells assessed as effect on change in golgi morphology at 10 uM after 1 hr by immunofluorescence method | 19182783 |
Vero | Function assay | 10 ug/ml | 1 hr | Inhibition of Arf1 in african green monkey Vero cells assessed as decrease in Arf1-GTP levels at 10 ug/ml after 1 hr | 19182783 |
Vero | Function assay | 10 uM | 1 hr | Inhibition of GBF1 in african green monkey Vero cells assessed as punctate and diffuse distribution of medial-Golgi marker giantin from TGN at 10 uM after 1 hr by immunofluorescence method | 19182783 |
Vero | Function assay | 10 ug/ml | 1 hr | Inhibition of Arf1 in african green monkey Vero cells assessed as punctate and diffuse distribution of medial-Golgi marker giantin at 10 ug/ml after 1 hr by immunofluorescence method | 19182783 |
Vero | Function assay | 10 ug/ml | 5 mins | Inhibition of Arf1 in african green monkey Vero cells assessed as rapid COPI redistribution from golgi at 10 ug/ml after 5 mins by immunofluorescence method | 19182783 |
Vero | Function assay | 10 ug/ml | 1 hr | Inhibition of Arf1 in african green monkey Vero cells assessed as tubule formation from trans golgi network and endosomes before its dispersal at 10 ug/ml after 1 hr by immunofluorescence method | 19182783 |
Vero | Function assay | 10 ug/ml | 1 hr | Inhibition of Arf1 in african green monkey Vero cells assessed as giantin positive punctate structures in contact with Sec31-positive ER exit site at 10 ug/ml after 1 hr by immunofluorescence method | 19182783 |
Vero | Function assay | 10 uM | 1 hr | Induction of GBF1 in african green monkey Vero cells assessed as punctate and diffuse distribution of cis-Golgi marker GM130 from TGN at 10 uM after 1 hr by immunofluorescence method | 19182783 |
Vero | Function assay | 10 ug/ml | 1 hr | Inhibition of Arf1 in african green monkey Vero cells assessed as punctate and diffuse distribution of cis-Golgi marker GM130 at 10 ug/ml after 1 hr by immunofluorescence method | 19182783 |
NRK | Function assay | 7 uM | 60 mins | Golgi-disturbing activity in golgi apparatus of rat NRK cells assessed as fusion of golgi membrane fusion with endoplasmic reticulum at 7 uM after 60 mins by Hoechst 3342 staining-based immunofluorescence microscopy | 20189813 |
HeLa R19 | Antiviral assay | 0.5 uM | 7 hrs | Antiviral activity against Coxsackievirus B3 infected in human HeLa R19 cells assessed as inhibition of viral replication at 0.5 uM after 7 hrs by luciferase reporter gene assay | 23805957 |
HeLa | Function assay | 5 uM | 30 to 60 mins | Induction of golgi apparatus disassembly in human HeLa cells at 5 uM after 30 to 60 mins by confocal microscopic analysis | 23805957 |
Arabidopsis thaliana root cells | Function assay | 90 uM | 30 mins | Induction of morphological changes of golgi apparatus in Arabidopsis thaliana root cells expressing ST-YFP/VHAa1-RFP at 90 uM after 30 mins by confocal laser scanning microscopic analysis | 23805957 |
HeLa R19 | Antiviral assay | 5 to 50 uM | 7 hrs | Antiviral activity against Coxsackievirus B3 infected in human HeLa R19 cells assessed as inhibition of viral replication at 5 to 50 uM after 7 hrs by luciferase reporter gene assay | 23805957 |
PC3 | Function assay | 50 nM | 72 hrs | Potentiation of 3 nM docetaxel-induced cytotoxicity against human PC3 cells assessed as decrease in cell viability at 50 nM after 72 hrs by trypan blue exclusion assay | 28462831 |
HeLa | Function assay | 18 uM | 3 hrs | Inhibition of alkaline phosphatase secretion in human HeLa cells at 18 uM incubated for 3 hrs | 31421965 |
PRP | Function Assay | 10 μM | abrogates SDF-1α-mediated CXCR7 externalization? | 24668750 | |
Vero | Function assay | 10 uM | Inhibition of GBF1 in african green monkey Vero cells assessed as inhibition of StxB-SS retrogade transport from endosomes to TGN at 10 uM by immunofluorescence method | 19182783 | |
Vero | Function assay | 10 ug/ml | Inhibition of Arf1 in african green monkey Vero cells assessed as inhibition of StxB-SS retrogade transport from endosomes to TGN at 10 ug/ml by immunofluorescence method | 19182783 | |
L02 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50<0.0004μM. | 28494251 | |
PC3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay, IC50=0.068μM. | 28494251 | |
HT-29 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay, IC50=0.16μM. | 28494251 | |
HepG2 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay, IC50=0.35μM. | 28494251 | |
LO2 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human LO2 cells after 72 hrs by MTT assay, IC50<0.001μM. | 29524728 | |
Bel7402 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay, IC50=0.024μM. | 29524728 | |
HL60 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay, IC50=0.025μM. | 29524728 | |
PC3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay, IC50=0.068μM. | 29524728 | |
Bel7402/5-FU | Antiproliferative assay | 72 hrs | Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by MTT assay, IC50=0.82μM. | 29524728 | |
VERO-E6 | Function assay | 48 hrs | Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of VERO-E6 cells after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging, IC50=0.02μM. | ChEMBL | |
VERO-E6 | Function assay | 48 hrs | Toxicity CC50 against VERO-E6 cells determined at 48 hours by high content imaging (same conditions as 2_LEY without exposure to 0.01 MOI SARS CoV-2 virus), CC50=0.06μM. | ChEMBL | |
MKN45 | Growth Inhibition Assay | IC50<0.001 μg/ml | 23793342 | ||
LOVO | Growth Inhibition Assay | IC50=0.12 μg/ml | 23793342 | ||
A549 | Growth Inhibition Assay | IC50=0.04 μg/ml | 23793342 | ||
MDA-MB-435 | Growth Inhibition Assay | IC50<0.001 μg/ml | 23793342 | ||
HepG2 | Growth Inhibition Assay | IC50<0.001 μg/ml | 23793342 | ||
HL-60 | Growth Inhibition Assay | IC50<0.001 μg/ml | 23793342 | ||
neural precursor cells | Function assay | Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay | 17417631 | ||
NCI60 | Cytostatic assay | Cytostatic activity against human NCI60 cells by SRB assay, GI50=0.0206μM. | 23805957 | ||
NCI60 | Cytostatic assay | Cytostatic activity against human NCI60 cells by SRB assay, TGI=3.48μM. | 23805957 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Brefeldin A (BFA)作用于HCT 116細胞,抑制內(nèi)酯抗生素和ATPase,作用于protein transport(蛋白轉(zhuǎn)運),IC50為0.2 μM,誘導(dǎo)癌細胞分化和凋亡。它還能提高同源重組修復(fù)效率,是CRISPR-mediated HDR的增強劑。Brefeldin A 也是自噬和線粒體自噬的抑制劑。 | ||
---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | Brefeldin A是一種真菌代謝產(chǎn)物,抑制內(nèi)質(zhì)網(wǎng)和高爾基體之間的傳輸,Brefeldin A導(dǎo)致膜蛋白分布受損。Brefeldin A處理HCT 116人結(jié)腸癌細胞,觀察到形態(tài)學(xué)的變化,表示細胞分化。Brefeldin A作用于腫瘤細胞,主要通過誘導(dǎo)分化和凋亡而發(fā)揮其細胞毒性作用。[1] 20 μg/mL Brefeldin A處理檢測條6小時,在10mM Indomethacin 和 30 μM L-NOARG存在時,完全廢除Bradykinin誘導(dǎo)的松弛。濃度為1 nM 到 1 mM之間的 20 μg/mL Brefeldin A處理,廢除Bradykinin誘導(dǎo)的[Ca2+]i降低。Brefeldin A作用于內(nèi)皮細胞,對Bradykinin 或 Substance P誘導(dǎo)的[Ca2+]i 提高沒有影響。[2] Brefeldin A 不影響GTPS與myr-rARF1的自發(fā)磷脂依賴性的結(jié)合,但完全廢除視網(wǎng)膜等滲提取物(RIE)的催化交換,2 μM Brefeldin A的半抑制濃度為2 μM。Brefeldin A 抑制多種膜轉(zhuǎn)運途徑。Brefeldin A作用于高爾基體膜或腦細胞質(zhì),抑制ADP-核糖基化因子特定的鳥嘌呤核苷酸交換活性。Brefeldin A完全抑制說明視網(wǎng)膜提取物包含ARF特定的鳥嘌呤核苷酸交換因子。Brefeldin A只部分抑制ADP-核糖基化因子(ARFs)釋放的視網(wǎng)膜等滲提取物(RIE)催化的GTPS,即使?jié)舛雀哌_300 μM時。[3] Brefeldin A誘導(dǎo)高爾基體與ER融合。Brefeldin A廢除 CERT 抑制劑HPA-12的抑制效果。Brefeldin A處理CHO細胞,使鞘磷脂的合成提高2到3倍。[4] 除了B-CLL細胞,Brefeldin A還造成多發(fā)性骨髓瘤(U266,NCI-H929),JURKAT,HeLa細胞,白血?。℉L60,K562,BJAB),結(jié)腸(HT-29),和前列腺,及腺樣囊性瘤細胞發(fā)生凋亡。25 ng/mL Brefeldin A處理 HF4.9 和 HF28RA 細胞,完全抑制細胞生長,而要完全抑制HF1A3 細胞生長則需要高劑量的Brefeldin A (75 ng/mL) 。50-75 ng/mL Brefeldin A 處理HF1A3, HF4.9 和 HF28RA細胞,24小時內(nèi)抑制細胞增殖,這種作用存在劑量依賴性,3H-胸甘的滲透幾乎完全停止,50 ng/ml處理時,HF1A3, HF4.9 和 HF28RA細胞分別抑制26%, 76%, 87%,75 ng/mL處理時,HF1A3, HF4.9 和 HF28RA細胞分別抑制75%, 87%, 92%。YO-PRO 1/PI檢測中,Brefeldin A誘導(dǎo)細胞死亡,這種作用存在劑量依賴性。[5] Brefeldin A可提高同源重組效率,是CRISPR-mediated HDR的增強劑[5]。 |
|||
---|---|---|---|---|
細胞實驗 | 細胞系 | 人類濾泡性淋巴瘤細胞系HF1A3,HF4.9 和HF28RA | ||
濃度 | 0 ng/mL-75 ng/mL | |||
孵育時間 | 5 天 | |||
方法 | 使用 YO-PRO 1/PI 和 SYTO16/PI 探針對細胞進行雙染色,測定HF1A3, HF4.9細胞活力。為了測定細胞增殖使用0–100 ng/mL Brefeldin A 在完全培養(yǎng)基中處理細胞20小時,然后加入1 μCi/mL [methyl-3H]-胸甘在37°C下再處理4小時。使用 Microbeta 計數(shù)儀對滲透的放射性胸甘進行閃爍計數(shù)。為了測定Brefeldin A治療的長期效果,細胞按初始濃度105 cells/mL接種,然后使用0-75 ng/mL Brefeldin A處理長達5天。在指定時間,移除細胞樣本,通過標(biāo)準臺酚藍排除法測定存活細胞數(shù)。 |
|||
實驗圖片 | 檢測方法 | 檢測指標(biāo) | 實驗圖片 | PMID |
Western blot | p53 / GRP78 | 22859938 | ||
Immunofluorescence | MTP / GBF1 ErbB3 / Calnexin FMNL1 / GM130 | 26267806 | ||
Growth inhibition assay | Cell viability | 28462831 |
分子量 | 280.36 | 分子式 | C16H24O4 |
CAS號 | 20350-15-6 | SDF | Download Brefeldin A (BFA) SDF |
Smiles | CC1CCCC=CC2CC(CC2C(C=CC(=O)O1)O)O | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 56 mg/mL ( (199.74 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項